HOLLISTON, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present to investors at the Sidoti August Virtual Investor Conference on August 16, 2023. Joining him will be Jennifer Cote, the company’s Chief Financial Officer and Treasurer.
The presentation will begin at 11:30 a.m. ET on Wednesday, August 16th and can be accessed live here. The presentation will also be archived on the Investor Relations section of the Harvard Bioscience website for a limited period of time.
Harvard Bioscience will also host virtual one-on-one meetings with investors on Wednesday August 16 and Thursday August 17. To register for the presentation or to schedule a one-on-one meeting, please visit www.sidoti.com/events.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Investor Contact:
Harvard Bioscience, Inc.
Investor Relations
(508) 893-3120
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.45 |
Daily Change: | 0.01 2.63 |
Daily Volume: | 523,784 |
Market Cap: | US$19.990M |
September 09, 2025 July 17, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load